|
1
|
World Health Organization, . Guidelines
for the prevention, care and treatment of persons with chronic
hepatitis B infection. March;2015.
|
|
2
|
Yan YP, Su HX, Ji ZH, Shao ZJ and Pu ZS:
Epidemiology of hepatitis B virus infection in China: Current
status and challenges. J Clin Transl Hepatol. 2:15–22.
2014.PubMed/NCBI
|
|
3
|
Zheng X, Wang J and Yang D: Antiviral
therapy for chronic hepatitis B in China. Med Microbiol Immunol
(Berl). 204:115–120. 2015. View Article : Google Scholar
|
|
4
|
Tang CM, Yau TO and Yu J: Management of
chronic hepatitis B infection: current treatment guidelines,
challenges, and new developments. World J Gastroenterol.
20:6262–6278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manzoor S, Saalim M, Imran M, Resham S and
Ashraf J: Hepatitis B virus therapy: What's the future holding for
us? World J Gastroenterol. 21:12558–12575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nebbia G, Peppa D and Maini MK: Hepatitis
B infection: Current concepts and future challenges. QJM.
105:109–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Expert Committee on Antiviral Therapy for
Special Patients with Chronic Hepatitis B, . Expert Consensus on
Antiviral Therapy for Special Patients with Chronic Hepatitis B: An
update in 2015. J Clin Hepatol. 31:1185–1192. 2015.
|
|
8
|
Chinese Society of Hepatology: CMA and
Society of Infectious Diseases, CMA, . Guidelines for Prevention
and Treatment of Chronic Hepatitis B (2015 Edition). Chin J Exp
Clin Infect Dis. 9:570–589. 2015.
|
|
9
|
European Association For The Study Of The
Liver: EASL clinical practice guidelines, . Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan
HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al:
Asian-Pacific clinical practice guidelines on the management of
hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li XN, Wu XP and Xiang TX: Characteristics
of liver biopsy in chronic hepatitis B virus-infected patients with
normal and minimally raised ALT. J Nanchang Univ. 51:73–76.
2011.
|
|
12
|
Liu GT, Li Y, Wei HL, Zhang H, Xu JY and
Yu LH: Mechanism of protective action of bicyclol against
CCl-induced liver injury in mice. Liver Int. 25:872–879. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang H and Li Y: Protective effect of
bicyclol on acute hepatic failure induced by lipopolysaccharide and
D-galactosamine in mice. Eur J Pharmacol. 534:194–201. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan SY, Dong H, Yu ZL, Zhao XY, Xiang CJ,
Wang H, Fong WF and Ko KM: Bicyclol, a synthetic
dibenzocyclooctadiene derivative, decreases hepatic lipids but
increases serum triglyceride level in normal and
hypercholesterolaemic mice. J Pharm Pharmacol. 59:1657–1662. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang
Z, Zhao H, Yan J and Cheng J: A randomized, multi-central,
controlled study of patients with hepatitis B e antigen-positive
chronic hepatitis B treated by adefovir dipivoxil or adefovir
dipivoxil plus bicyclol. Hepatol Int. 6:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han Y, Shi JP, Ma AL, Xu Y, Ding X-D and
Fan J-G: Randomized, vitamin E-controlled trial of bicyclol plus
metformin in non-alcoholic fatty liver disease patients with
impaired fasting glucose. Clin Drug Investig. 34:1–7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin CL and Kao JH: Risk stratification for
hepatitis B virus related hepatocellular carcinoma. J Gastroenterol
Hepatol. 28:10–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lei J, Sockolow P, Guan P, Meng Q and
Zhang J: A comparison of electronic health records at two major
Peking University Hospitals in China to United States meaningful
use objectives. BMC Med Inform Decis Mak. 13:962013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu YN, Chen H and Li Y: Effect of bicyclol
on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22
tumour-bearing mice. Basic Clin Pharmacol Toxicol. 104:300–305.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao XM, Chen H and Li Y: Protective effect
of bicyclol on liver injury induced by hepatic warm
ischemia/reperfusion in rats. Hepatol Res. 39:833–842. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou XE, Xu N, Yao HP and Chen Z: Bicyclol
attenuates pro-inflammatory cytokine and chemokine productions in
CpG-DNA-stimulated L02 hepatocytes by inhibiting p65-NF-κB and
p38-MAPK activation. Pharmazie. 65:206–212. 2010.PubMed/NCBI
|
|
22
|
Bao XQ and Liu GT: Involvement of HSP70 in
the protection of bicyclol on apoptosis of HepG2 cells intoxicated
by d-galactosamine. J Asian Nat Prod Res. 12:313–323. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu HY, Wang BL, Zhao J, Yao XM, Gu Y and
Li Y: Protective effect of bicyclol on tetracycline-induced fatty
liver in mice. Toxicology. 261:112–118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu GT: Bicyclol: A novel drug for
treating chronic viral hepatitis B and C. Med Chem. 5:29–43. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Qiang L and Pei L: Assessment of
Bicyclol tablets' Effect on Viral CHB. Chin J Exp Clin Virol.
21:165–167. 2007.
|
